Novartis’ Rhapsido Approved by FDA as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib), an oral treatment for adult patients with chronic spontaneous urticaria (CSU)…
Read More...
Read More...
